The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticoster...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2016-12, Vol.63 (11), p.1490-1493
Hauptverfasser:	Del Castillo, Maria, Romero, Fabian A., Argüello, Esther, Kyi, Chrisann, Postow, Michael A., Redelman-Sidi, Gil
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adrenal Cortex Hormones - adverse effects Adrenal Cortex Hormones - therapeutic use Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use BRIEF REPORTS Cell Cycle Checkpoints Child Child, Preschool Female Humans Immune system Immunologic Factors - administration & dosage Immunologic Factors - therapeutic use Immunotherapy - adverse effects Infection - epidemiology Infection - etiology Infection - microbiology Infection - virology Infliximab - adverse effects Infliximab - therapeutic use Male Medical Records Melanoma Melanoma - complications Melanoma - drug therapy Melanoma - microbiology Middle Aged Molecules Retrospective Studies Risk Factors Spectrum analysis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/ciw539